Gamida Cell Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMDA research report →
Companywww.gamida-cell.com
Gamida Cell Ltd. , a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
- CEO
- Abigail L. Jenkins
- IPO
- 2018
- Employees
- 143
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $4.34M
- P/E
- -0.08
- P/S
- 2.43
- P/B
- -1.65
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -94.96%
- Op Margin
- -4094.06%
- Net Margin
- -3531.17%
- ROE
- 1148.30%
- ROIC
- -86.17%
Growth & Income
- Revenue
- $1.78M · 0.00%
- Net Income
- $-62,996,000 · 59.19%
- EPS
- $-0.42 · 82.64%
- Op Income
- $-73,038,000
- FCF YoY
- -4.46%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 1.03
- Avg Volume
- 21.71M
Get TickerSpark's AI analysis on GMDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 24 | MOCH KENNETH I | other | 200,000 |
| Jan 31, 24 | WILLS STEPHEN T | other | 200,000 |
| Jan 31, 24 | Tomasello Shawn | other | 200,000 |
| Jan 31, 24 | ADAMS JULIAN | other | 200,000 |
| Jan 31, 24 | Simantov Ronit | other | 480,319 |
| Jan 31, 24 | Borrello Ivan M. | other | 200,000 |
| Jan 31, 24 | Patterson Joshua F. | other | 480,319 |
| Jan 31, 24 | Korfin Michele Ilene | other | 480,319 |
| Oct 19, 23 | Jenkins Abigail L. | other | 109,013 |
| Oct 19, 23 | Jenkins Abigail L. | other | 217,954 |
Our GMDA Coverage
We haven't published any research on GMDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GMDA Report →